You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, December 2013
|
| DOI | 10.1186/1750-1172-8-198 |
| Pubmed ID | |
| Authors |
Thomas Morel, Francis Arickx, Gustaf Befrits, Paolo Siviero, Caroline van der Meijden, Entela Xoxi, Steven Simoens |
| Abstract |
National payers across Europe have been increasingly looking into innovative reimbursement approaches - called managed entry agreements (MEAs) - to balance the need to provide rapid access to potentially beneficial orphan medicinal products (OMPs) with the requirements to circumscribe uncertainty, obtain best value for money or to ensure affordability. This study aimed to identify, describe and classify MEAs applied to OMPs by national payers and to analyse their practice in Europe. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 20% |
| United Kingdom | 1 | 20% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Scientists | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 203 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | <1% |
| Ireland | 1 | <1% |
| Unknown | 200 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 49 | 24% |
| Researcher | 30 | 15% |
| Student > Ph. D. Student | 19 | 9% |
| Student > Bachelor | 14 | 7% |
| Other | 13 | 6% |
| Other | 29 | 14% |
| Unknown | 49 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 27 | 13% |
| Economics, Econometrics and Finance | 21 | 10% |
| Social Sciences | 14 | 7% |
| Business, Management and Accounting | 11 | 5% |
| Other | 30 | 15% |
| Unknown | 54 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2023.
All research outputs
#3,080,428
of 25,371,288 outputs
Outputs from Orphanet Journal of Rare Diseases
#415
of 3,105 outputs
Outputs of similar age
#34,420
of 320,858 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#6
of 42 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,858 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.